Nemes Rush Group’s Edwards Lifesciences EW Stock Holding History

Nemes Rush Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.69K	Sell	96 -9	-9%	-$742	﹤0.01%	577
2025 Q4	$8.95K	Buy	105 +9	+9%	+$739	﹤0.01%	562
2025 Q3	$7.47K	Sell	96 -6	-6%	-$469	﹤0.01%	515
2025 Q2	$7.98K	Buy	102 +6	+6%	+$447	﹤0.01%	499
2025 Q1	$6.96K	Sell	96 -179	-65%	-$12.8K	﹤0.01%	504
2024 Q4	$20.4K	Sell	275 -8,924	-97%	-$625K	﹤0.01%	393
2024 Q3	$879K	Sell	9,199 -1,770	-16%	-$129K	0.13%	91
2024 Q2	$1.01M	Buy	10,969 +1,651	+18%	+$146K	0.14%	85
2024 Q1	$890K	Sell	9,318 -45,919	-83%	-$3.86M	0.13%	92
2023 Q4	$4.21M	Buy	55,237 +2,995	+6%	+$208K	0.68%	44
2023 Q3	$3.62M	Buy	52,242 +4,301	+9%	+$346K	0.66%	45
2023 Q2	$4.52M	Buy	+47,941	New	+$4.17M	0.8%	42

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nemes Rush Group's EW Position: Q1 2026 in Review

Nemes Rush Group reduced its Edwards Lifesciences (EW) stake by 8.6% in Q1 2026, selling an estimated $742 and leaving 96 shares worth $7.69K. The position accounts for ﹤0.01% of the portfolio, ranked #577.

Nemes Rush Group first reported a position in EW in Q2 2023 and has held it in 12 quarters since. The position peaked at $4.52M in Q2 2023. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Nemes Rush Group held 96 shares of Edwards Lifesciences worth $7.69K as of Q1 2026.
Nemes Rush Group sold 9 Edwards Lifesciences shares in Q1 2026, an estimated $742.
Edwards Lifesciences made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #577 holding.
Nemes Rush Group first reported a position in Edwards Lifesciences in Q2 2023 and has held it in 12 quarters since.
Nemes Rush Group's Edwards Lifesciences position peaked at $4.52M in Q2 2023.
1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.